Enhanced Detection and Treatment of Autoimmune Diseases through Targeted Pathogenic Age-Associated B Cells

The present invention relates to novel methods and systems for predicting, diagnosing, and treating autoimmune diseases by targeting pathogenic age-associated B cells, leveraging the detection and modulation of DEF6 and SWAP-70 proteins to improve disease outcomes.

The original patent disclosed methods for treating autoimmune diseases by targeting pathogenic age-associated B cells. However, it had limitations in predicting disease risk, tracking disease progression, and identifying subjects at risk. The present inventive concept addresses these limitations by providing novel methods and systems for early detection, personalized treatment, and monitoring of autoimmune diseases.

The inventive concept comprises novel methods for predicting autoimmune disease risk by detecting levels of pathogenic age-associated B cells using nucleic acids encoding human DEF6 and SWAP-70 proteins. It also includes systems for treating autoimmune diseases, comprising therapeutic modules administering these nucleic acids and monitoring modules tracking the level of pathogenic age-associated B cells over time. Additionally, the inventive concept encompasses methods for identifying subjects at risk of developing autoimmune diseases and determining the efficacy of treatments. These novel approaches improve disease outcomes by enabling early intervention, personalized treatment, and real-time monitoring.

The present inventive concept introduces novel methods and systems that are not obvious from the original patent. The use of DEF6 and SWAP-70 proteins for predicting disease risk, tracking disease progression, and identifying subjects at risk represents a significant advancement over the prior art. The inventive concept's emphasis on personalized treatment and real-time monitoring also distinguishes it from existing approaches.

Alternative embodiments of the inventive concept could include the use of different nucleic acid delivery methods, such as viral vectors or liposomes, to target pathogenic age-associated B cells. Variations could also involve the integration of machine learning algorithms to analyze gene expression data and predict disease risk. Additionally, the inventive concept could be adapted for use in other diseases characterized by aberrant B cell activity.

The present inventive concept has significant commercial potential in the autoimmune disease treatment market, which is projected to reach $15.6 billion by 2025. The inventive concept's ability to enable early detection, personalized treatment, and real-time monitoring positions it for widespread adoption in the healthcare industry, with potential applications in pharmaceutical development, diagnostic testing, and personalized medicine.